Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.31 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in brain inhibitory neurons (246 nCPM) | 1.00 |
| chemistry Open Targets | compounds already reach it: otenabant, azd2207, sad448 +9 | 1.00 |
| trials ClinicalTrials.gov | 2 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 11 Parkinson's papers of 799 | 0.67 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 1225
Sealed predictions
- CNR1 in dopamine neurons, braak+0.04 (p 0.928) → +0.11 (p 0.787)receipt 1231
Swarm cases
receipt 1231: CNR1 in dopamine neurons, braak
- power
- full sample +0.08 (p 0.761, n 18), 95% CI -0.40 to +0.53. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.02 (p 0.949, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.02 (p 0.928, n 18). could be the mix.
- skeptic
- leave-one-out range -0.04 to +0.17, sign flips 4; without severely affected donors +0.08 (p 0.761, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CNR1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts